Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cytek Biosciences, Inc. - Common Stock
(NQ:
CTKB
)
4.480
+0.080 (+1.82%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cytek Biosciences, Inc. - Common Stock
< Previous
1
2
3
Next >
TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026
November 12, 2025
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year
November 06, 2025
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
October 29, 2025
Supports ISAC in Mission to Extend Flow Cytometry Reach Worldwide; Unveils Programs Offering Instrument Award and Research Grants
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth
October 15, 2025
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA
September 10, 2025
Spectral Flow Cytometry Pioneer Unveils Innovations Accelerating Efficiency and Discovery
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
May 29, 2025
Improved Sample Throughput, Automation Capabilities and Updated Hardware Design
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences Reports First Quarter 2025 Financial Results
May 08, 2025
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
April 29, 2025
Company to Conduct Demonstrations, Educational Workshops and Tutorials at Key Industry Events
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System
March 18, 2025
Increasing Accessibility for Flow Cytometry Applications in Emerging and Established Markets
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025
December 30, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
November 19, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
November 07, 2024
World’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific Discoveries
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
September 18, 2024
Industry Leaders to Explore Cytek’s Advanced Cell Analysis Solutions at ICCS and ESCCA
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
August 21, 2024
Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
July 30, 2024
Expanding Capabilities and Streamlining Experimental Workflows
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences Announces $50 Million Stock Repurchase Program
June 06, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
May 30, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
May 28, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
May 20, 2024
New Enhanced Small Particle (ESP™) Detection Option for Cytek Northern Lights™ and Cytek Aurora™ Systems Expands Capabilities of Small Particle Research
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences Reports First Quarter 2024 Financial Results
May 08, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
April 30, 2024
Company to Conduct Educational Workshops and Tutorials at CYTO and AAI’s IMMUNOLOGY2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
April 29, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Names William McCombe Chief Financial Officer
March 19, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
March 07, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
February 28, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences to Participate in Upcoming Investor Conferences
February 07, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
February 07, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
January 17, 2024
Cytek’s Cutting-Edge Spectral Flow Cytometry Technology, Specialized Staff, Tools and Solutions Set New Benchmarks for Cell Analysis
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
January 08, 2024
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023
From
Cytek Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.